65,437 trials
Bradycardia
Primary: Number of MRI Related Patient Adverse Events and/or Adverse Device Effects During MRI Visit — 0 number of MRI related patient adverse ev
HIV · Rabies
Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml
Conduct Disorder · Oppositional Defiant Disorder · Attention Deficit Disorder With Hyperactivity
Primary: Social Skills Rating System (Parent Report) — 46.37; 43.25; 45.02; 41.66 units on a scale
To Healthy Volunteer · Virtual Lesions for Aphasia
Primary: The Change of Reaction Time Between Before and After Stimulation in Each Session (MTG, STG, Sham) — 110.65; -14.25; 25.29 msec
Myocardiopathies · Ischemia, Myocardial · Arrythmia
Primary: MMP-2 — 173493.4; 139012.4 pg/ml
Corneal Astigmatism
Primary: Reduction of Astigmatism — -0.75; -0.88 diopter
Hypertension
Primary: The Mean Maximum Absolute Change in Systolic Blood Pressure From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1…
Postoperative Pain · Adverse Effects
Primary: Patients With Pain: Numerical Rating Scale (NRS-11(0-10): 0:no Pain and 10:Severe/Worst Pain) ≥ 4 — 19; 5; 11 participants
Bipolar Disorder
Primary: Clinical Global Impression-Efficacy Index (CGI-EI) — 1.58; 1.52 Units on the scale — p=0.59
Myopia
Primary: Subject Reported Ease of Removal — 47.2; 75.6 percentage of participants
Chronic Myelogenous Leukemia
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) - Part 1 — 1; 1; 0 Participants
Anemia · Chronic Kidney Disease
Primary: Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33) — 2.157; 1.969 g/dL
Graft-Versus-Host Disease
Primary: The Percentage of Participants Experiencing Acute GVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 45; 18 percentage of participants
Asthma
Primary: Change at Day 92 From Baseline in Mean Asthma Control Questionnaire (ACQ) Scores (Intent-toTreat Analysis) — -1.23; -1.10; -1.26; -1.31 Scores on a scale — p=0.435
Transitional Cell Carcinoma · Bladder Cancer
Primary: Median Progression-Free Survival (PFS) — 2.56; 1.58 months — p=0.939